CEP170

Across TCGA pan-cancer cohorts, CEP170 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CEP170 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CEP170 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CEP170 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, COAD, and PDAC are the cancer types where CEP170 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.831	1.000	.007	42	view →
COAD	DFS	Median	All	0.886	1.000	.020	12	view →
PDAC	OS	Tertile	II,III,IV	0.279	0.464	.012	6	view →
LUAD	DFS	Median	All	0.993	0.809	.007	4	view →
LSCC	DFS	Quartile	III,IV	0.774	1.000	.020	3	view →
HNSC	DFS	Median	All	0.564	0.739	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CEP170–CCRCC (OS)

Open the CCRCC breakdown →